A SARS-CoV-2 variant carrying the Spike protein amino acid change D614G has become
the most prevalent form in the global pandemic. Dynamic tracking of variant frequencies …

In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …

Background In the RV144 trial, the estimated efficacy of a vaccine regimen against human
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …

Background The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214
booster vaccine are not known. Methods In this ongoing, phase 2–3 study, we …

Recent studies of human immunodeficiency virus type 1 (HIV-1) infection in humans and of
simian immunodeficiency virus (SIV) in rhesus monkeys have shown that resolution of the …

Clinical evidence suggests that cellular immunity is involved in controlling human
immunodeficiency virus–1 (HIV-1) replication. An animal model of acquired immune deficiency …

The precise identification of the HIV-1 envelope glycoprotein (Env) responsible for
productive clinical infection could be instrumental in elucidating the molecular basis of HIV-1 …

Omicron Neutralization and mRNA-1273 Boosters Neutralization of the omicron variant was
assessed in serum samples obtained from persons who had received an mRNA-1273 …

Heterologous prime/boost regimens have the potential for raising high levels of immune
responses. Here we report that DNA priming followed by a recombinant modified vaccinia …